Program avoidsthe need to connect to the Internet while delivering a presentation
PEACE-1 ancillary study: Biomarkers predict prognosis but not abiraterone benefit in mCSPC
Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Cabozantinib/atezolizumab improves PFS, shows no significant OS benefit in mCRPC
According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Darolutamide plus ADT shows rPFS benefit in mHSPC
According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001).
Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC
On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).
